Core Viewpoint - Jiangsu Wuzhong's subsidiary, Datou Medical, has received a termination letter from Regen Biotech, which demands the cancellation of Datou Medical's exclusive distribution rights for the AestheFill product in mainland China, raising concerns about the company's future in the medical aesthetics sector amid ongoing financial scandals [1][2]. Group 1: Company Response and Legal Actions - Jiangsu Wuzhong has initiated a response plan upon receiving the termination letter and is in communication with Regen, indicating that legal action may be taken if necessary to protect its rights [2]. - Regen's reasons for termination include allegations that Datou Medical transferred exclusive distribution rights to its parent company, and concerns over Jiangsu Wuzhong's legal violations affecting the product's reputation [2]. Group 2: Market Impact and Financial Performance - The change in the registration agent for AestheFill from Datou Medical to Lizhen (Beijing) Biotechnology Co., owned by Regen, introduces uncertainty regarding the previously secure exclusive distribution agreement [4]. - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion yuan, a decline of 28.64% year-on-year, with the medical aesthetics segment generating 330 million yuan, a significant increase of over 40 times [4]. - If the exclusive distribution agreement is ultimately terminated, Datou Medical would lose its rights to sell AestheFill, leading to a substantial decrease in revenue and profit for the medical aesthetics segment in the latter half of the year [5].

Group 1: Medical Aesthetics Business Development - The company plans to increase investment in the medical aesthetics sector, aiming to enhance the market recognition and reputation of the Suya Medical Aesthetics brand. In 2025, new medical aesthetics institutions are planned to open in Jiangsu and Shanghai [2][3] - In 2024, the medical aesthetics segment achieved revenue of 179 million yuan and is currently profitable. The company will continue to focus on self-built facilities and expand in high-consumption areas like the Yangtze River Delta [5][6] Group 2: Shareholder Engagement and Stock Performance - In 2024, the actual controller and some executives completed a round of share buybacks, demonstrating confidence in the company's long-term investment value [3][4] - The company is committed to a "long-termism" approach, focusing on stable operations and long-term value creation, despite current market pressures affecting stock prices [4][6] Group 3: Strategic Business Direction - The company is dedicated to developing medical aesthetics and biopharmaceuticals, emphasizing a long-term strategy and resource optimization to enhance operational efficiency and profitability [3][5] - Future business expansion will include exploring new industries and opportunities, with a focus on maintaining a balanced approach to growth and avoiding reckless expansion [5][6] Group 4: Market Conditions and Company Response - The company's stock price has been under pressure due to macroeconomic factors, industry developments, and investor expectations. The company aims to improve product quality, brand building, and customer service to enhance overall competitiveness [6][7] - New medical aesthetics facilities are under construction, with plans for trial operations expected around mid-year [6][7]

【文/王力 编辑/周远方】 4月23日晚间，医药流通巨头九州通宣布就将以6.73亿元价格揽入奥园美谷20%股权，拟成为其重整后的潜在控股股东。这一动作标志着九州通从医美供应 链服务商向终端医疗机构运营者的战略跃升。 奥园美谷虽手握连天美等知名医美机构资源，却因连年亏损陷入资不抵债困境，而九州通凭借多年医美产业链布局经验，试图通过资本运作盘活这一优质资 产，构建"供应链+终端服务"的闭环生态。 实则九州通早在2016年便以投资爱美客切入医美赛道，后续通过合作华熙生物、朗姿医疗等企业，逐步覆盖上游耗材供应与中游机构服务，2023年医美业务 营收同比翻倍至3.42亿元。然而，其核心医药流通业务利润持续承压，2024年前三季度净利润下滑近7%，亟需医美等高增长领域打开新局面。此次低价控 股奥园美谷，既是对其医美版图的补强，亦是对业绩突围的豪赌——若整合成功，九州通可依托自身供应链优势赋能奥园美谷降本增效，同时借后者33万会 员资源加速产品下沉，实现协同增值。 九州通拟6.73亿入主奥园美谷，医美版图再下一城 4月23日晚间，医药流通巨头九州通发布公告，其全资子公司湖北九州产业园区运营管理有限公司（以下简称"九州产投公 ...